ES2085936T3 - Preparado para aplicar sustancias activas en forma de microgotas. - Google Patents

Preparado para aplicar sustancias activas en forma de microgotas.

Info

Publication number
ES2085936T3
ES2085936T3 ES91114163T ES91114163T ES2085936T3 ES 2085936 T3 ES2085936 T3 ES 2085936T3 ES 91114163 T ES91114163 T ES 91114163T ES 91114163 T ES91114163 T ES 91114163T ES 2085936 T3 ES2085936 T3 ES 2085936T3
Authority
ES
Spain
Prior art keywords
microdrops
prepared
preparation
active substances
apply active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91114163T
Other languages
English (en)
Other versions
ES2085936T5 (es
Inventor
Gregor Cevc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27435001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2085936(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19914107152 external-priority patent/DE4107152C2/de
Priority claimed from DE19914107153 external-priority patent/DE4107153A1/de
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2085936T3 publication Critical patent/ES2085936T3/es
Publication of ES2085936T5 publication Critical patent/ES2085936T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION TRATA DE UN PREPARADO PARA LA APLICACION DE SUSTANCIAS ACTIVAS EN UN MOLDEO PEQUEÑO, CONCRETAMENTE CON UNA ENVOLTURA DE MEMBRANA DE UNA MOLECULA ANFIFILER DE UNA O VARIAS CAPAS, CONCRETAMENTE CON UNAS GOTAS DE LIQUIDO PROVISTAS CON UNA SUSTANCIA PORTADORA DE ANFIFILER, CONCRETAMENTE PARA EL TRANSPORTE DE LAS SUSTANCIAS ACTIVAS EN Y MEDIANTE BARRERAS NATURALES Y CONSTRICCIONES COMO EPIDERMIS Y SIMILARES. EL PREPARADO TIENE UN CONTENIDO DE UNA SUSTANCIA CON UN BORDE ACTIVADO QUE CORRESPONDE HASTA EL 99% DE MOL DEL CONTENIDO DE ESTA SUSTANCIA, MEDIANTE EL CUAL SE ALCANZA EL PUNTO DE SOLUBILIDAD DE LAS GOTAS PEQUEÑAS. EL PREPARADO SIRVE PARA LA APLICACION NO INVASIBA DE ANTIDIABETICAS, CONCRETAMENTE DE INSULINA. LA INVENCION TRATA ADEMAS DE UN METODO PARA LA ELABORACION DE ESTOS PREPARADOS.
ES91114163T 1990-08-24 1991-08-23 Preparado para aplicar sustancias activas en forma de microgotas. Expired - Lifetime ES2085936T5 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE4026833 1990-08-24
DE4026834 1990-08-24
DE4026834 1990-08-24
DE4026833 1990-08-24
DE19914107152 DE4107152C2 (de) 1991-03-06 1991-03-06 Präparate zur nichtinvasiven Verabreichung von Antidiabetica
DE19914107153 DE4107153A1 (de) 1991-03-06 1991-03-06 Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
DE4107152 1991-03-06
DE4107153 1991-03-06

Publications (2)

Publication Number Publication Date
ES2085936T3 true ES2085936T3 (es) 1996-06-16
ES2085936T5 ES2085936T5 (es) 2005-03-01

Family

ID=27435001

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91114163T Expired - Lifetime ES2085936T5 (es) 1990-08-24 1991-08-23 Preparado para aplicar sustancias activas en forma de microgotas.

Country Status (9)

Country Link
US (1) US20070042030A1 (es)
EP (1) EP0475160B8 (es)
JP (1) JP3765579B2 (es)
AT (1) ATE134133T1 (es)
CA (1) CA2067754C (es)
DE (1) DE59107402D1 (es)
DK (1) DK0475160T4 (es)
ES (1) ES2085936T5 (es)
WO (1) WO1992003122A1 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2139757C (en) 1992-07-08 2009-04-14 Gunther Maierhofer Liposomes, method of preparing the same and use thereof in the preparation of drugs
DE4306475A1 (de) * 1993-03-02 1994-09-08 Ensenat Pedro Gonzalez Liposomen, enthaltend Chlorhexidindiacetat oder Chlorhexidindigluconat
DE4308121A1 (de) * 1993-03-15 1994-09-22 Rhone Poulenc Rorer Gmbh Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems
US6663885B1 (en) * 1993-03-15 2003-12-16 A. Natterman & Cie Gmbh Aqueous liposome system and a method for the preparation of such a liposome system
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
JP3136352B2 (ja) * 1996-01-22 2001-02-19 参天製薬株式会社 角結膜疾患治療剤
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
TW592713B (en) 1998-05-11 2004-06-21 Ciba Sc Holding Ag Use of nanodispersions in cosmetic end formulations
US7381423B2 (en) 1998-05-11 2008-06-03 Ciba Specialty Chemicals Corp. Use of nanodispersions in cosmetic end formulations
US6302863B1 (en) 1998-06-16 2001-10-16 Nikolai Tankovich Method for removal of lipids via a perfluorocarbon tumescent solution
BR9816014A (pt) * 1998-09-01 2001-05-08 Idea Ag Transporte eletricamente controlado de penetrantes carregados através de barreiras
US6290987B1 (en) * 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
MXPA00006196A (es) * 1998-10-23 2003-07-21 Idea Ag Metodo para desarrollar, evaluar y utilizar asociaciones de macromoleculas y agregados complejos para obtener mejores tasas de asociacion/desasociacion controlable y carga efectiva.
DE69825495T2 (de) * 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
SI1031347T1 (en) * 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
WO2001035998A1 (en) * 1999-11-12 2001-05-25 Pharmaderm Laboratories, Ltd. Compositions for transdermal and transmucosal administration of therapeutic agents
BR0001144B1 (pt) * 2000-02-21 2013-10-22 Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase
DE60122304T2 (de) * 2000-04-12 2007-08-09 Liplasome Pharma A/S Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
US6451808B1 (en) * 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
IL139177A0 (en) * 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
GB0028706D0 (en) * 2000-11-24 2001-01-10 Unilever Plc Cosmetic composition
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
AU2003233396B2 (en) * 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
CN1703199B (zh) * 2002-10-11 2010-04-28 伊迪亚股份公司 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20070042998A1 (en) * 2005-08-19 2007-02-22 Annica Karkkainen Medical cosmetic method for reducing adipose tissue and for initiating lipolysis through subcutaneous and intracutaneous injections and customized composition compounded from pharmaceutical agents for use therein
DE102006013623A1 (de) * 2005-11-23 2007-05-24 Pro Natura Gesellschaft für gesunde Ernährung mbH Mittel zur Verminderung des verwertbaren Kaloriengehalts der Nahrung und zur therapeutischen Gewichtsabnahme. Insbesondere zur Anwendung bei Adipositas (Fettsucht)
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
CN101410123A (zh) 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的双氯芬酸和β－环糊精的制剂
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
DE102007028360B4 (de) 2007-06-15 2016-04-14 Marcus Asam Wirkstoffkombination für kosmetische Zubereitungen
CN105434353A (zh) 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
WO2011021704A1 (ja) * 2009-08-21 2011-02-24 アース製薬株式会社 薬剤を植物体に取り込ませる方法
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
EP2531047B1 (en) 2010-02-05 2024-11-13 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
US20120190609A1 (en) * 2010-08-30 2012-07-26 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
CN103547258B (zh) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
WO2013057208A1 (en) 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9381147B2 (en) * 2014-10-20 2016-07-05 Johnson & Johnson Consumer Inc. Compositions comprising zwitterionic ester ammonioalkanoates
US9943816B2 (en) 2014-10-20 2018-04-17 Eastman Chemical Company Amphoteric ester sulfonates
US9533951B2 (en) 2014-10-20 2017-01-03 Eastman Chemical Company Heterocyclic amphoteric compounds
US10406088B2 (en) 2015-01-20 2019-09-10 TetraDerm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
US9993408B2 (en) 2015-09-17 2018-06-12 Johnson & Johnson Consumer Inc. Compositions comprising zwitterionic alkyl-alkanoylamides and/or alkyl alkanoates
US11414380B2 (en) 2015-09-17 2022-08-16 Eastman Chemical Company Amphoteric compounds
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
EP3787601B1 (en) * 2018-04-30 2025-10-08 Purdue Research Foundation Liposomal nano formulation of combinational antibiotics and the uses thereof
CN111904932B (zh) * 2019-05-08 2023-06-20 北京德立福瑞医药科技有限公司 一种含有糖皮质激素的胶束制剂及其制备方法
DE202019002134U1 (de) 2019-05-16 2019-06-06 Penta Phi Eg Liposomales Glutathion
CN117298043A (zh) * 2023-10-24 2023-12-29 山东大学 一种纳米水凝胶前驱体及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64397A0 (en) * 1981-01-07 1982-02-28 Weder Hans G Process for the preparation of liposomal medicaments
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
GB8321913D0 (en) * 1983-08-15 1983-09-14 Acacia Chem Ltd Spray method
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
JPS6295134A (ja) * 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
DK86988A (da) * 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US4937078A (en) * 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
US5104661A (en) * 1989-08-14 1992-04-14 Technology Unlimited, Inc. Reverse loading of liposomes

Also Published As

Publication number Publication date
EP0475160A1 (de) 1992-03-18
US20070042030A1 (en) 2007-02-22
JPH05502042A (ja) 1993-04-15
ATE134133T1 (de) 1996-02-15
EP0475160B2 (de) 2004-07-14
ES2085936T5 (es) 2005-03-01
DK0475160T3 (da) 1996-07-08
CA2067754A1 (en) 1992-02-25
CA2067754C (en) 2002-06-04
EP0475160B1 (de) 1996-02-14
JP3765579B2 (ja) 2006-04-12
DK0475160T4 (da) 2004-11-22
DE59107402D1 (de) 1996-03-28
EP0475160B8 (de) 2004-11-03
WO1992003122A1 (de) 1992-03-05

Similar Documents

Publication Publication Date Title
ES2085936T3 (es) Preparado para aplicar sustancias activas en forma de microgotas.
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
DE69637061D1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
DE60038848D1 (de) Feste Arzneizusammensetzungen mit gesteuerter Wirkstoffabgabe hergestellt mittels eines Thermoformverfahrens
HUT42943A (en) Process for production of efficient on skin medical preparatives containing as carrying substance liposomes
EP0458894A4 (en) LIPID EXCIPIENT FOR NASAL ADMINISTRATION AND OTHER LOCAL APPLICATIONS.
DK0551820T3 (da) Smagsmarkeret farmaceutisk præparat
DE3867866D1 (de) Liposomzubereitung und ihre herstellung.
ES8104720A1 (es) Un procedimiento para la preparacion de composiciones lipo- somicas de substancias activas grasosolubles
ZA946698B (en) Medical device for the administration of active ingredients or drugs at very low doses particularly homeopathic drugs
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
ES2170813T3 (es) Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina.
FI95653C (fi) Menetelmä lääkeaineen anto- ja/tai annostelumuodon valmistamiseksi
PT89802A (pt) Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas
WO1994017792A3 (en) Compositions and methods for transdermal drug delivery
CS9001136A2 (en) Method of transdermal therapeutical system's production with active substance's graded liberation and application for active substances' local or systemic administration
ES2058988T3 (es) Preparacion de medicamentos para el tratamiento sistemico de peces ornamentales y utiles.
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
ATE199646T1 (de) Halbfeste arzneimittel sowie verfahren zu deren herstellung
DE3883335D1 (de) Brenzcatechincarbonsaeurederivate, ihre herstellung und verwendung als wirkstoffe fuer arzneimittel.
KR910021238A (ko) 켈로이드 치료제
DE3865201D1 (de) Fluessiges, wismuthaltiges arzneipraeparat, verfahren zum herstellen desselben und seine verwendung.
DE60032372D1 (de) Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
ATE179070T1 (de) Dithranol enthaltendes arzneimittel zur topischen anwendung sowie herstellungsverfahren
EP1288311A3 (en) Method for testing small pharmaceutically active molecules in the activation of Pax4 and production of insulin producing beta-cells

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475160

Country of ref document: ES